哌甲酯治疗轻度阿尔茨海默病社区老年退伍军人冷漠症状:双盲随机安慰剂对照试验
该12周双盲随机安慰剂对照试验在60名轻度阿尔茨海默病社区退伍军人中评估哌甲酯对冷漠的效果。结果显示,调整基线后哌甲酯组在第4、8、12周冷漠改善显著优于安慰剂组,第12周认知、功能状态、照料者负担、CGI评分及抑郁也均更优。
要点
- 哌甲酯可显著改善轻度阿尔茨海默病患者的冷漠症状。
- 哌甲酯还改善认知、功能状态、照料者负担、CGI及抑郁。
- 研究仅纳入男性退伍军人,外推需谨慎。
核心结论
- 哌甲酯改善轻度阿尔茨海默病社区退伍军人的冷漠症状。
- 哌甲酯还改善认知、功能状态、照料者负担、CGI评分及抑郁。
研究设计与样本
- 12周前瞻性双盲随机安慰剂对照试验,纳入60名轻度阿尔茨海默病社区退伍军人。
- 主要结局为冷漠评估量表-临床版,次要结局包括认知、功能状态、CGI、照料者负担及抑郁,于基线及第4、8、12周测量。
主要发现
- 调整基线后,哌甲酯组在第4、8、12周冷漠改善显著优于安慰剂组。
- 第12周哌甲酯组认知、功能状态、照料者负担、CGI评分及抑郁改善也优于安慰剂组。
- 参与者均为男性,平均年龄77岁(SD=8)。
临床怎么用
- 对轻度阿尔茨海默病伴冷漠的社区老年退伍军人,哌甲酯可能改善冷漠及认知、功能、照料者负担和抑郁。
- 临床决策需结合患者具体情况,并注意研究人群限于男性退伍军人。
局限性
- 样本量较小(N=60),仅纳入社区居住的男性退伍军人。
- 研究为期12周,长期疗效与安全性未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Apathy is a common behavioral problem in Alzheimer's disease. Apathy has profound consequences, such as functional impairment, higher service utilization, higher caregiver burden, and increased mortality. The authors' objective was to study the effects of methylphenidate on apathy in Alzheimer's disease. METHOD: A 12-week, prospective, double-blind, randomized, placebo-controlled trial (methylphenidate versus placebo) was conducted in community-dwelling veterans (N=60) with mild Alzheimer's disease. The primary outcome for apathy (Apathy Evaluation Scale-Clinician) and secondary outcomes for cognition (Mini-Mental State Examination, Modified Mini-Mental State Examination), functional status (activities of daily living, instrumental activities of daily living), improvement and severity (Clinical Global Impressions Scale [CGI]), caregiver burden (Zarit Burden Scale), and depression (Cornell Scale for Depression in Dementia) were measured at baseline and at 4, 8, and 12 weeks. RESULTS: Participants were all men (77 years old, SD=8). After adjusting for baseline, the methylphenidate group had significantly greater improvement in apathy than the placebo group at 4 weeks, 8 weeks, and 12 weeks. At 12 weeks, there was also greater improvement in cognition, functional status, caregiver burden, CGI scores, and depression in the methylphenidate group compared with the placebo group. CONCLUSIONS: Methylphenidate improved apathy in a group of community-dwelling veterans with mild Alzheimer's disease. Methylphenidate also improved cognition, functional status, caregiver burden, CGI scores, and depression.
引用
- Padala PR, Padala KP, Lensing SY, et al. Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial. Am J Psychiatry. 2017. PMID: 28945120. doi:10.1176/appi.ajp.2017.17030316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。